(L8I7) NASDAQ-100 Daily Leverage - Overview
Etf: Tech, Nasdaq, Leveraged, UCITS, ETF
| Risk 5d forecast | |
|---|---|
| Volatility | 43.2% |
| Relative Tail Risk | 0.60% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.20 |
| Alpha | -4.69 |
| Character TTM | |
|---|---|
| Beta | 0.584 |
| Beta Downside | 0.837 |
| Drawdowns 3y | |
|---|---|
| Max DD | 44.38% |
| CAGR/Max DD | 0.99 |
Description: L8I7 NASDAQ-100 Daily Leverage November 30, 2025
Lyxor UCITS NASDAQ-100 Daily Leverage (XETRA:L8I7) is a Germany-domiciled ETF that provides leveraged exposure to the NASDAQ-100 index, targeting a daily multiple (typically 2×) of the index’s performance. It falls under the “Trading – Leveraged/Inverse Equity” category, meaning its returns are amplified and reset each trading day, which can lead to significant divergence from the underlying index over longer periods.
Key metrics to watch: the ETF’s expense ratio (currently around 0.30% p.a.) is modest for a leveraged product, while its 30-day rolling volatility typically exceeds 50%, reflecting the amplified risk profile. The fund’s tracking error is usually under 1% on a daily basis, but compounding effects can cause larger deviations over weeks or months.
Economic and sector drivers: the NASDAQ-100 is heavily weighted toward technology and consumer discretionary firms, so earnings growth in cloud computing, AI, and semiconductor markets directly influence the ETF’s performance. Additionally, U.S. monetary policy-particularly changes in the federal funds rate-affects the cost of leverage and can impact the fund’s net asset value.
Given the high-frequency nature of leveraged ETFs, investors should monitor intraday price movements and be prepared to adjust positions quickly; a back-test of the fund’s performance during recent rate-hike cycles shows a 15%-plus swing in a single month.
For a deeper dive into the fund’s risk-adjusted returns and scenario analysis, you might explore the ValueRay platform’s analytics tools.
What is the price of L8I7 shares?
Over the past week, the price has changed by -5.37%, over one month by -5.89%, over three months by -5.46% and over the past year by +5.18%.
Is L8I7 a buy, sell or hold?
What are the forecasts/targets for the L8I7 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 1787.7 | 27.1% |
L8I7 Fundamental Data Overview February 03, 2026
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.01b EUR (1.01b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.01b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.01b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 25.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.07% (E(1.01b)/V(1.01b) * Re(8.07%) + (debt-free company))
Discount Rate = 8.07% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)